CTOs on the Move

HealthiVibe

www.healthivibe.com

 
HealthiVibe captures patient insights around clinical trial design and patient-centered initiatives. We believe the patient voice is critical in healthcare.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Dan Kett
Director Information Technology Services Profile

Similar Companies

Bloomios

Bloomios is a U.S. based leading hemp and nutraceutical GMP manufacturer specializing in product development, formulation, packaging, and design. They provide white label and private label services for businesses looking to expand into the hemp industry.

Wockhardt USA

Wockhardt USA is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Archemix

Archemix Corp. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Nature`s Bounty Corporation

The Nature`s Bounty Co. has a history of championing health and wellness tracing back 145 years. Putting science and the highest quality standards at the heart of our business, the brands of The Nature`s Bounty Co. are some of the most trusted in the world. Always motivated by our commitment to excellence, our vision for health and wellness has inspired leading brands such as Nature`s Bounty, Sundown Naturals, Solgar, Holland & Barrett, Osteo Bi-Flex, Ester-C, MET-Rx, Pure Protein, Balance, Body Fortress, Puritan`s Pride and Organic Dr., among others. As a leading global manufacturer, marketer, distributor and retailer of vitamins, nutritional supplements, sports & active nutrition and ethical beauty products, The Nature`s Bounty Co. is committed to supporting wellness in all its forms.

OnKure Therapeutics

OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure`s drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.